Rhythm Pharmaceuticals (RYTM) Insider Trading & Ownership $103.01 -1.22 (-1.17%) As of 09:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.10%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)10Amount OfInsider Selling(Last 12 Months)$27.35M Get RYTM Insider Trade Alerts Want to know when executives and insiders are buying or selling Rhythm Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RYTM Insider Buying and Selling by Quarter Rhythm Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/21/2025Joseph ShulmanInsiderSell4,188$100.07$419,093.16 8/13/2025Hunter C SmithCFOSell3,477$96.00$333,792.00 8/12/2025Christopher Paul GermanCAOSell1,500$95.00$142,500.00 8/12/2025Hunter C SmithCFOSell24,611$96.33$2,370,777.63 8/11/2025Joseph ShulmanInsiderSell3,984$90.08$358,878.72 7/29/2025Pamela J CramerInsiderSell1,520$85.93$130,613.60 7/9/2025Christopher Paul GermanCAOSell3,817$80.75$308,222.75 7/9/2025Hunter C SmithCFOSell42,120$80.48$3,389,817.60 7/9/2025Joseph ShulmanInsiderSell7,969$77.78$619,828.82 7/9/2025Pamela J CramerInsiderSell15,572$77.13$1,201,068.36 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 7/2/2025Alastair GarfieldInsiderSell1,319$64.81$85,484.39 6/10/2025Christopher Paul GermanCAOSell2,069$67.19$139,016.11 6/6/2025Pamela J CramerInsiderSell7,031$68.05$478,459.55 4/29/2025Pamela J CramerInsiderSell7,031$65.09$457,647.79 4/29/2025Yann MazabraudEVPSell6,745$65.08$438,964.60 4/8/2025Pamela J CramerInsiderSell20,760$60.14$1,248,506.40 4/8/2025Yann MazabraudEVPSell17,750$60.99$1,082,572.50 3/21/2025Christopher Paul GermanCAOSell344$54.23$18,655.12 3/14/2025Yann MazabraudEVPSell75,000$51.48$3,861,000.00 2/19/2025Christopher Paul GermanCAOSell635$57.22$36,334.70 2/19/2025David P MeekerCEOSell9,896$57.22$566,249.12 2/19/2025Hunter C SmithCFOSell2,215$57.22$126,742.30 2/19/2025Jennifer Kayden LeeEVPSell2,035$57.22$116,442.70 2/19/2025Joseph ShulmanInsiderSell1,228$57.22$70,266.16 2/12/2025Jennifer Kayden LeeEVPSell1,815$56.39$102,347.85 2/11/2025Hunter C SmithCFOSell1,296$57.51$74,532.96 2/11/2025Joseph ShulmanInsiderSell794$57.51$45,662.94 2/10/2025Jennifer Kayden LeeEVPSell4,189$58.91$246,773.99 2/4/2025David P MeekerCEOSell4,278$59.43$254,241.54 2/4/2025Hunter C SmithCFOSell1,678$59.43$99,723.54 2/4/2025Jennifer Kayden LeeEVPSell1,447$59.43$85,995.21 2/4/2025Joseph ShulmanInsiderSell1,281$59.43$76,129.83 11/11/2024Jennifer Kayden LeeEVPSell66,861$66.33$4,434,890.13 11/11/2024Joseph ShulmaninsiderSell13,281$66.44$882,389.64 11/7/2024Pamela J CramerInsiderSell4,688$65.00$304,720.00 9/17/2024Jennifer L GoodDirectorSell31,751$52.40$1,663,752.40 9/10/2024Lynn A TetraultDirectorSell17,501$49.65$868,924.65 9/9/2024Pamela J CramerInsiderSell4,099$50.03$205,072.97 (Data available from 1/1/2013 forward) RYTM Insider Trading Activity - Frequently Asked Questions Who is on Rhythm Pharmaceuticals' Insider Roster? The list of insiders at Rhythm Pharmaceuticals includes Alastair Garfield, Christopher Paul German, David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Jennifer L Good, Joseph Shulman, Lynn A Tetrault, Pamela J Cramer, William T Roberts, and Yann Mazabraud. Learn more on insiders at RYTM. What percentage of Rhythm Pharmaceuticals stock is owned by insiders? 6.10% of Rhythm Pharmaceuticals stock is owned by insiders. Learn more on RYTM's insider holdings. Which Rhythm Pharmaceuticals insiders have been selling company stock? The following insiders have sold RYTM shares in the last 24 months: Alastair Garfield ($85,484.39), Christopher Paul German ($660,096.36), David P Meeker ($2,604,765.34), Hunter C Smith ($7,696,643.79), Jennifer Kayden Lee ($5,326,722.98), Jennifer L Good ($1,663,752.40), Joseph Shulman ($8,143,497.52), Lynn A Tetrault ($1,083,967.65), Pamela J Cramer ($6,467,180.27), and Yann Mazabraud ($6,091,956.82). How much insider selling is happening at Rhythm Pharmaceuticals? Insiders have sold a total of 702,483 Rhythm Pharmaceuticals shares in the last 24 months for a total of $39,824,067.52 sold. Rhythm Pharmaceuticals Key ExecutivesDr. David P. Meeker M.D. (Age 70)Chairman, President & CEO Compensation: $1.35MMr. Hunter C. Smith M.B.A. (Age 55)CFO & Treasurer Compensation: $757.32k3 recent tradesMr. Joseph Shulman (Age 48)Chief Technical Officer Compensation: $677.27k3 recent tradesMr. Yann Mazabraud (Age 51)Executive VP & Head of International Compensation: $936.91k3 recent tradesMs. Jennifer Lee (Age 48)Executive VP & Head of North America Compensation: $727.14kMr. Christopher German (Age 53)Corporate Controller, Principal Accounting Officer & Executive Director 4 recent tradesMr. David ConnollyHead of Investor Relations & Corporate CommunicationsMr. Jim FlahertySenior VP & General CounselMs. Sarah RyanVice President of Sales & MarketingMs. Pamela J. Cramer (Age 49)Chief Human Resources Officer 5 recent trades More Insider Trading Tools from MarketBeat Related Companies BioNTech Insider Buying Teva Pharmaceutical Industries Insider Buying Summit Therapeutics Insider Buying Genmab A/S Insider Buying Viatris Insider Buying Moderna Insider Buying BridgeBio Pharma Insider Buying Elanco Animal Health Insider Buying Verona Pharma PLC American Depositary Share Insider Buying Roivant Sciences Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:RYTM) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access